Answers are grounded in this paper and cite their sources.
QALYs and Value Assessment Mayvis Rebeira PhD, Canadian Health Policy Institute ABSTRACT This literature review highlights the limitations of using Quality-Adjusted Life-Years or QALYs, in assessing the value of therapies through its use in cost-effectiveness analysis. Objective:
No takes yet. Share an insight, caveat, or question.
Mayvis Rebeira (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: